PRELUDE THERAPEUTICS INCORPORATED - COMMON STOCK

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

09 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

04 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

23 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

12 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

08 Nov 2021 09:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

07 Oct 2021 09:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

02 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

12 Aug 2021 07:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors

19 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

02 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

11 May 2021 07:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference

05 May 2021 07:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update

16 Mar 2021 08:00:02 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences

03 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

11 Jan 2021 18:20:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Pricing of Upsized Public Offering

07 Jan 2021 00:12:43 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Launch of Proposed Public Offering

04 Jan 2021 16:16:38 By Nasdaq GlobeNewswire